Chinese Osteoporotic Fracture Registration Network Platform
CORN
Construction of Chinese Osteoporotic Fracture Registration Network Platform and National Cooperative Network
1 other identifier
observational
50,000
1 country
39
Brief Summary
China has gradually entered an aging society, and the incidence of osteoporotic fractures is increasing rapidly. Although the harm of osteoporotic fracture is huge, its diagnostic rate in China is still low. China still lacks a national osteoporotic fracture registration system, which has been established in many countries. The purpose of this study is to establish a Chinese osteoporotic fracture registration network platform (CORN), which will be helpful for the long-term comprehensive management of osteoporotic fracture population in China. This platform will help to establish a large prospective clinical cohort database of osteoporotic fractures and high-risk population in China.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2021
Typical duration for all trials
39 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2021
CompletedFirst Submitted
Initial submission to the registry
April 1, 2022
CompletedFirst Posted
Study publicly available on registry
April 21, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2024
CompletedFebruary 25, 2025
March 1, 2024
3.1 years
April 1, 2022
February 23, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (10)
Total number of patients enrolled in 3 years
The number of patients enrolled in Chinese Osteoporotic Fracture Registration Network Platform (CORN) in 3 years
3 years
Age distribution
Age distribution of enrolled patients
3 years
Sex ratio
Sex ratio of enrolled patients
3 years
Body Mass Index (BMI) of enrolled patients
Weight and height will be combined to report BMI in kg/m\^2
3 years
Quality of life of enrolled patients
Quality of life will be assessed with a five-level EuroQol five-dimensional (EQ-5D-5L) questionnaire (Chinese version). Measurement results of EQ-5D-5L will be used to generate values with an EQ-5D-5L Value Set for China. And a higher value means a better QOL.
3 years
Fall risk assessment of enrolled patients
Fall risk will be assessed with Morse Fall Scale (Chinese version). The minimum value is 0, and the maximum value is 125. A higher value means a higher risk of fall.
3 years
Fracture risk Assessment of enrolled patients
Fracture risk will be assessed with Fracture Risk Assessment Tool (FRAX). And a higher value means a higher risk of fracture.
3 years
Bone turnover markers (BTMs)
BTMs of enrolled patients will be tested and analyzed.
3 years
Bone mineral density of enrolled patients
Bone mineral density (BMD) should be measured with dual energy X-ray absorptiometry (DXA).
3 years
Health record analysis
A comprehensive evaluation of patients' medical records, including symptoms, physical examination, treatments, etc.
3 years
Secondary Outcomes (2)
Follow-up rate after enrollment
Every year of the 3 years
Usage rate of anti-osteoporosis drugs
Every year of the 3 years
Study Arms (1)
Osteoporotic fracture
No additional intervention will be administered.
Interventions
No additional intervention will be administered.
Eligibility Criteria
Patients at high risk of fracture.
You may qualify if:
- Patients with hip osteoporotic fracture.
- Patients with vertebral osteoporotic fracture.
- Patients with low T-score ( ≤ -2.5) and at least one risk factor (e.g., history of osteoporotic fractures in other sites, a parental history of hip fracture, age ≥ 65 years, BMI \< 18.5kg/m2, current smoking).
- Patients with very low T-score (\< -3.0).
- The ten year probability of fracture by FRAX: major osteoporosis fracture ≥20%, or hip fracture ≥3%.
You may not qualify if:
- Patients who are unwilling to participate in the trial, have poor compliance and do not sign informed consent.
- Patients judged as unqualified participants by clinicians.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Peking Union Medical College Hospitallead
- Xuanwu Hospital, Beijingcollaborator
- Beijing Hospitalcollaborator
- Tianjin First Central Hospitalcollaborator
- Hebei Medical University Third Hospitalcollaborator
- The Second Affiliated Hospital of Harbin Medical Universitycollaborator
- Peking University Third Hospitalcollaborator
- Second Affiliated Hospital, School of Medicine, Zhejiang Universitycollaborator
- Ruijin Hospitalcollaborator
- Affiliated Hospital of Nantong Universitycollaborator
- Shanghai Changzheng Hospitalcollaborator
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technologycollaborator
- Second Xiangya Hospital of Central South Universitycollaborator
- Nanfang Hospital, Southern Medical Universitycollaborator
- The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicinecollaborator
- First Affiliated Hospital of Fujian Medical Universitycollaborator
- Second Affiliated Hospital of Guangzhou Medical Universitycollaborator
- The Seventh Affiliated Hospital of Sun Yat-sen Universitycollaborator
- Sichuan Province Orthopetic Hospitalcollaborator
- The Second Affiliated Hospital of Chongqing Medical Universitycollaborator
- Daping Hospital, Army Medical Center of PLAcollaborator
- First Affiliated Hospital Xi'an Jiaotong Universitycollaborator
- The First Affiliated Hospital of Zhengzhou Universitycollaborator
- Second Affiliated Hospital of Soochow Universitycollaborator
- The First Affiliated Hospital with Nanjing Medical Universitycollaborator
- Peking University Shenzhen Hospitalcollaborator
- General Hospital of Ningxia Medical Universitycollaborator
- Second Affiliated Hospital of Wenzhou Medical Universitycollaborator
- Beijing Jishuitan Hospitalcollaborator
- Zhejiang Hospitalcollaborator
- Shenzhen People's Hospitalcollaborator
- Xiangya Hospital of Central South Universitycollaborator
- Beijing Friendship Hospitalcollaborator
- Shanghai 6th People's Hospitalcollaborator
- Shanghai East Hospital of Tongji Universitycollaborator
- Zhongda Hospitalcollaborator
- First Affiliated Hospital of Jinan Universitycollaborator
- Fujian Provincial Hospitalcollaborator
Study Sites (39)
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
Beijing Hospital
Beijing, Beijing Municipality, China
Beijing Shijingshan Hospital
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
The Second Medical Center of The General Hospital of the People's Liberation Army
Beijing, Beijing Municipality, China
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Daping Hospital, Army Medical Center of PLA
Chongqing, Chongqing Municipality, China
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Fuzhou Second Hospital
Fuzhou, Fujian, China
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
Lunjiao Hospital of Shunde Foshan
Foshan, Guangdong, China
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Guangzhou, Guangdong, China
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Shenzhen Second People's Hospital
Shenzhen, Guangdong, China
The Seventh Affiliated Hospital, Sun Yat-sen University
Shenzhen, Guangdong, China
Guizhou Provincial Orthopedics Hospital
Guiyang, Guizhou, China
The Third Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
The First People's hospital of Changzhou
Changzhou, Jiangsu, China
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China
Nantong First People's Hospital
Nantong, Jiangsu, China
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000, China
Dalian Hospital of Chinese Traditional and Western Medicine
Dalian, Liaoning, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, China
Tenth People's Hospital of Tongji University
Shanghai, Shanghai Municipality, China
Sichuan Province Orthopedic Hospital
Chengdu, Sichuan, China
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
West China Fourth Hospital, Sichuan University
Chengdu, Sichuan, China
Tianjin First Central Hospital
Tianjin, Tianjin Municipality, China
Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region
Ürümqi, Xinjiang, China
The Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Huamei Hospital, University of Chinese Academy of Sciences
Ningbo, Zhejiang, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Weibo Xia, MD
Peking Union Medical College Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 1, 2022
First Posted
April 21, 2022
Study Start
December 1, 2021
Primary Completion
December 31, 2024
Study Completion
December 31, 2024
Last Updated
February 25, 2025
Record last verified: 2024-03